Start Over

PD-L1 Expression Status Predicting Survival in Pulmonary Pleomorphic Carcinoma.

Authors :: Hisakane K
Seike M
Sugano T
Matsuda K
Kunugi S
Nakamichi S
Matsumoto M
Miyanaga A
Noro R
Minegishi Y
Kubota K
Gemma A
Source :: Anticancer research [Anticancer Res] 2021 May; Vol. 41 (5), pp. 2501-2509.
Publication Year :: 2021
Abstract: Background/aim: Pulmonary pleomorphic carcinoma (PPC) is a rare and aggressive tumor that is resistant to treatment. The expression and prognostic value of programmed cell death-ligand 1 (PD-L1) and its association with epithelial-mesenchymal transition (EMT) in PPC remains unclear.<br />Patients and Methods: The expression of PD-L1 and EMT markers, such as E-cadherin, vimentin, zinc finger E-box-binding homeobox 1 (ZEB-1), and cellular mesenchymal-epithelial transition (c-Met) was evaluated by immuno - histochemistry in 16 patients with PPC who underwent surgical resection.<br />Results: The expression of PD-L1 varied between carcinomatous and sarcomatous areas. Positive correlations between PD-L1 and vimentin expression in carcinomatous areas (r=0.668, p=0.005) and PD-L1 and ZEB-1 expression in sarcomatous areas (r=0.562, p=0.023) were found. High PD-L1 and ZEB-1 expression in sarcomatous areas predicted poor survival (p=0.045 and p=0.012, respectively).<br />Conclusion: PD-L1 expression associated with ZEB1 expression in the sarcomatoid component of patients with PPC may be useful for predicting patient prognosis.<br /> (Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)